Phase 1/2Completed

Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT)

A Phase 1/2a, Open-Label, Multicenter, Dose-Escalation Study to Evaluate the Safety and Tolerability of Intravenous Administration of RGI-2001 in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT)

Sponsor
Regimmune Corporation (Industry)
Enrollment
68 enrolled
Conditions
Graft Versus Host Disease
Interventions
RGI-2001; Calcineurin Inhibitors; Allogeneic Hematopoietic Stem Cell Transplantation; Conditioning Regimen; Allogeneic Bone Marrow Transplantation; Methotrexate; Mofetil Mycophenolate; sirolimus
Ages
adults, older adults
Registry
NCT01379209

Full record on ClinicalTrials.gov

From the registry

The clinical trial is a Phase 1/2a, open-label, multi-center, dose-escalation study to evaluate the safety, tolerability and pharmacokinetic profile of RGI-2001 in patients undergoing AHSCT, with radiation or non-radiation myeloablative preparative treatment. The study will be separated into two parts; a dose escalation phase to assess safety, followed by a large expansion phase to further evaluate the pharmacologic effects of either a Maximum Tolerated Dose, Maximum Feasible Dose or optimal pharmacologically active dose of RGI-2001. The initial dose escalation safety portion of the study (Part 1) will include higher risk patients and limit the unrelated donor transplants. After safety is established in part 1 of the study, the second portion of the study will expand the enrollment criteria and allow transplantation by either related or unrelated donors. This study will endeavor to identify the dose range at which RGI-2001 has an acceptable safety profile, at which biologic activity is observed, and to guide possible dose levels to utilize in later phase studies based on…

Primary outcomes

  • The maximum tolerated dose (MTD) or maximum feasible dose (MFD) of RGI-2001

History

  1. Last registry update

  2. Study completion

  3. Primary completion

  4. Started

  5. Registered